Moderna has recently announced the results of their phase 3 trials for two mRNA vaccines, namely mRNA-1345, a vaccine targeting the respiratory syncytial virus (RSV), and mRNA-4157, an individualized neoantigen therapy for cancer.
The mRNA-1345 vaccine has been tested on a sample group of 35,541 individuals, half of whom received the actual vaccine while the other half received a placebo. Preliminary analysis, conducted after reaching 50% of the set target, reveals that the vaccine is effective with an efficacy of 83.7% (95% CI, 66.0-92.2%) in preventing the disease with at least two symptoms. Furthermore, it shows an efficacy of 82.4% (95% CI, 34.8-95.3%) when considering at least three symptoms. However, it is worth noting that some participants experienced mild to moderate adverse effects, with a rate of 2.8%, regardless of whether they received the actual vaccine or the placebo. Overall, the vaccine demonstrates satisfactory efficacy with minimal side effects.
Moving on to the mRNA-4157 vaccine, it has been tested on a group of 157 patients with advanced melanoma who have undergone complete tumor removal. These patients were divided into two groups, with the experimental group receiving both KEYTRUDA and mRNA-4157, while the control group received KEYTRUDA alone. The results showed a 49% reduction (95% CI, 0.288-0.906) in disease recurrence when patients received mRNA-4157, along with a 62% reduction in cancer spread. Encouraged by these findings, Moderna is planning to conduct phase 3 trials and expand the study to include other types of cancer.
In conclusion, Moderna’s mRNA-1345 and mRNA-4157 vaccines have shown promising results in combating viral infections and treating cancer, respectively. With further research and clinical trials, these vaccines hold the potential to make a significant impact on public health.
TLDR: Moderna has released phase 3 trial results for mRNA-1345, a vaccine targeting RSV, and mRNA-4157, a personalized neoantigen therapy for cancer. The mRNA-1345 vaccine demonstrated an efficacy of 83.7% in preventing the disease with at least two symptoms. The mRNA-4157 vaccine showed a 49% reduction in disease recurrence and a 62% reduction in cancer spread among melanoma patients. Moderna plans to conduct phase 3 trials and expand the study to include other types of cancer. These vaccines have great potential in improving public health.
Leave a Comment